Fig. 2
From: Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications
Possible rational combination treatments for HH/GLI-associated cancers simultaneously targeting HH/GLI and HH-regulated immunosuppressive and tumor-promoting signals. The efficacy, response rate and durability of the therapeutic effect of HH/GLI pathway inhibition is likely to increase upon combination of approved HH/SMO antagonists with small molecules and/or biologics such as neutralizing or blocking antibodies developed for the selective inhibition of immune suppression and tumor-promoting inflammation